December 31, 2011 -- The 2012 J.P. Morgan Healthcare Conference includes several China-related events, which we describe; Harbin Pharma was given an official go-ahead to complete an $870 million corporate restructuring with its parent, Harbin Pharmaceutical Group; China Health Resource retained legal counsel to facilitate an international acquisition strategy; China announced new Foreign Direct Investment Guidelines that will encourage foreigners to invest in China biotechnology companies; and Yunnan Baiyao Group began operations in its new $396 million production facility. More details….
Stock Symbols: (SHA: 600664) (OTCBB: CHRI) (SHE: 000538)